Guselkumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), G-BA (Germany) and NICE (England), among others, recommended or restricted guselkumab, while NYE METODER (Norway) did not recommend it.
HAS (France) has been harder on guselkumab than on its own caseload: it refused 3 of 8 decisive submissions here (38%), against a base rate of 11% across everything it has assessed.
Assessment has run over 8.8 years, from 5 Oct 2017 at AWMSG (Wales) to 23 Aug 2026 at NYE METODER (Norway).
HAS (France) changed its position: not recommended on 3 Oct 2018, recommended by 15 Jul 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for guselkumab.
The file is active: 30 of 56 records date from 2023 or later.
The programme is broad: 15 distinct indication wordings are recorded for guselkumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
9 of these 56 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess guselkumab, on 5 Oct 2017; CIPM (Spain) did not open a file until 17 Dec 2025 — an unusually long tail of 8.2 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 10 years in total.
13 of the 13 agencies here assessed guselkumab more than once, PBAC (Australia) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
guselkumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for guselkumab reads 25 recommended, 12 not recommended, 9 restricted and 4 deferred to NICE, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 15 Jul 2026 | Indication extension | SMR substantial · ASMR V | source |
| G-BA (Germany) | 18 Jun 2026 | Tremfya — benefit assessment §35a | added benefit: not proven | source |
| TLV (Sweden) | 23 Dec 2025 | Tremfya ingår i högkostnadsskyddet med begränsning för ytterligare en patientgrupp | restricted subsidy | source |
| CIPM (Spain) | 17 Dec 2025 | Indicaciones terapéuticas autorizadas: Enfermedad de Crohn Tremfya está indicado para el tratamiento de pacientes adulto… | not financed by the SNS (financed 2026-03) | source |
| PBAC (Australia) | 2023 | Chronic plaque psoriasis | The PBAC advised that the July 2020 recommendation could be revoked, noting that there was… | source |
51 further decisions for guselkumab, across 13 agencies, are not shown here. They include the most recent record on file, 23 Aug 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 39 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 56 decisions for guselkumab from 13 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.